Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) CAO Michael Megna sold 36,260 shares of the stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $94.43, for a total transaction of $3,424,031.80. Following the sale, the chief accounting officer owned 12,697 shares in the company, valued at $1,198,977.71. This represents a 74.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Price Performance
KNSA traded up $2.49 during trading on Tuesday, hitting $93.29. 1,021,631 shares of the stock traded hands, compared to its average volume of 705,858. The business has a 50 day moving average price of $79.39 and a 200 day moving average price of $60.29. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $98.48. The company has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.04.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The company had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. On average, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current year.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
A number of institutional investors and hedge funds have recently bought and sold shares of KNSA. Allworth Financial LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. Arizona State Retirement System raised its holdings in Kiniksa Pharmaceuticals International by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock valued at $648,000 after buying an additional 209 shares during the last quarter. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International by 21.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after buying an additional 223 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after buying an additional 237 shares during the period. Finally, First Trust Advisors LP boosted its position in Kiniksa Pharmaceuticals International by 3.1% during the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after buying an additional 293 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a research note on Friday. The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus price target of $100.57.
Check Out Our Latest Report on Kiniksa Pharmaceuticals International
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Read More
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
